Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy
VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies
Clinical Scorecard: Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy
At a Glance
| Category | Detail |
|---|
| Condition | T cell receptor-based natural killer cell therapy |
| Key Mechanisms | GMP lentiviral vector manufacturing |
| Target Population | Patients with solid tumors |
| Care Setting | Manufacturing of allogeneic cell therapies |
Key Highlights
- Collaboration between VIVEbiotech and Zelluna since 2018.
- Focus on off-the-shelf therapies for solid tumors.
- Challenges include achieving high purity, consistent quality, and scalability.
- Importance of lentiviral vector performance for gene transfer efficiency.
- Need for flexible, scalable platforms to support innovation.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with solid tumors requiring innovative therapies.
High-performing vectors are crucial for safety and manufacturing predictability.
Clinical Best Practices
- Ensure GMP compliance in manufacturing processes.
- Utilize stable cell lines for consistent vector production.
- Incorporate automation in manufacturing and quality control.
Related Resources & Content
